Deepak Mangla, MD
Ophthalmology · Lapeer, MINPI 1942648902
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,140 of the $13,974 with a category attached, or 65.4%. Genentech USA, Inc. accounts for 89.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2023 at $5,248 and has fallen 91.7% since, to $434 in 2025. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $194.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$12K
- Regeneron Healthcare Solutions, Inc.$597
- Alimera Sciences, Inc.$242
- Genentech, Inc.$199
- Astellas Pharma US Inc$115
- ANI Pharmaceuticals, Inc.$107
- plus $230 from 7 others
What the payments were for
- Consulting fees$9,14065%
- Travel & lodging$2,60719%
- Food & beverage$2,22716%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 27 | $12,484 |
| Regeneron Healthcare Solutions, Inc. | 20 | $597 |
| Alimera Sciences, Inc. | 2 | $242 |
| Genentech, Inc. | 5 | $199 |
| Astellas Pharma US Inc | 4 | $115 |
| ANI Pharmaceuticals, Inc. | 4 | $107 |
| Biogen | 3 | $87 |
| Apellis Pharmaceuticals, Inc. | 1 | $37 |
| Coherus Oncology, Inc. | 2 | $32 |
| LKC Technologies, Inc. | 1 | $19 |
| Sandoz | 1 | $19 |
| Biotissue Holdings Inc. | 1 | $18 |
| Bausch & Lomb Americas Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,974 in reported general payments places this provider in the 90th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 61 | $2,939 |
| Latanoprost | 41 | $1,041 |
| ErythromycinErythromycin Base | 59 | $809 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 39 | $734 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 43 | $553 |
| Ketorolac Tromethamine | 20 | $476 |
| Brimonidine Tartrate | 22 | $201 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Lapeer
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
- David TukelDearborn$91K
- Yannis PaulusAnn Arbor$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.